The latest disclosed insider activity at Core Scientific, Inc. (NASDAQ:CORZ) involves Todd M. Duchene, the Chief Legal and Administrative Officer. On May 18, 2026, Duchene completed a sale of common stock valued at $231,497. The disposition covered 10,000 shares of the company's common stock, with selling prices ranging across two distinct bands: between $23.1244 and $23.7575.
The details of the transaction indicate that Duchene sold 9,600 shares at a weighted average price of $23.1244 per share. These individual sales were recorded within a range from $22.66 to $23.62. Separately, an additional 400 shares were disposed of at a weighted average price of $23.7575 per share, with corresponding individual sale prices falling between $23.69 and $23.82.
It is important to note that these sales were not executed unilaterally; rather, they were carried out in accordance with a Rule 10b5-1 trading plan that Duchene had previously established on December 5, 2025. Following the completion of this sale, Duchene's direct holding of Core Scientific common stock stands at 1,960,348 shares.
The insider selling report is contextualized by several recent developments concerning Core Scientific’s market performance and strategic trajectory. Over the past year, Core Scientific shares have risen significantly, showing an 110% surge in value. However, this growth has been accompanied by considerable volatility, evidenced by a beta of 5.45.
On the operational front, the company remains focused on shifting its core business model from Bitcoin mining activities toward establishing colocation infrastructure. This strategic transition was highlighted in the Q1 2026 earnings report. For that quarter, Core Scientific recorded revenues totaling $115.24 million, alongside an earnings per share (EPS) loss of -1.06 USD.
Further evidence of capacity expansion includes the significant addition of power resources; approximately 1.2 gigawatts were added during the year, including a new facility measuring 430 megawatts located in Hunt County, Texas. These developments underscore an active investment cycle aimed at solidifying the company's infrastructure base.
Beyond internal operations and financial performance, external analyst activity provides additional color. Specifically, BTIG recently updated its assessment of Core Scientific, raising its price target to $33 from a previous level of $23 while maintaining a Buy rating for the stock. Furthermore, the company successfully held its 2026 Annual Meeting of Stockholders. During this meeting, five individuals were elected to serve on the board, with their terms extending until the 2027 meeting.
These combined developments - the insider trading activity, the reported Q1 earnings mixed results, the large-scale infrastructure expansion, and positive analyst rating adjustments - collectively offer investors a detailed view into Core Scientific’s current strategic focus and operational challenges. The company continues to navigate profitability hurdles while executing a substantial pivot in its service model.